BYBengi Ruken Yavuz

Bengi Ruken Yavuz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bengi Ruken Yavuz has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single-Cell Mapping of Malignant Signaling Networks Guides Drug Combinations

    by Bengi Ruken Yavuz, Hyunbum Jang, Ruth Nussinov

    Single-cell breast cancer atlases reveal malignant, immune, and stromal diversity; however, how the recurrent signaling pathways drive untreated malignant-cell states and could inform combination therapy remains unclear. Here, we analyzed 15,753 malignant cells from untreated primary breast tumors using a cell-resolved network framework. Individual transcriptomes were projected onto a protein-protein interaction network, partitioned into Leiden communities, and annotated by pathway enrichment. Pathway recurrence was evaluated against matched null models preserving community size, protein-network degree, and gene detection rate. Before null correction, recurrent pathways included PI3K/AKT, MAPK, JAK/STAT, and HIF-1 (hypoxia-inducible factor 1) signaling. After correction, HIF-1 emerged as the dominant recurrent signal across patients, indicating convergence of diverse upstream pathways on a shared hypoxia- and stress-adaptive malignant-cell program. The recurrent JAK/STAT, cAMP, glucagon, oxytocin, and thyroid hormone signaling suggest inflammatory, metabolic, and endocrine crosstalk. These findings support rational drug combinations targeting HIF-1 together with upstream PI3K/AKT/mTOR, MAPK, or JAK/STAT signaling.

  • Open Access

    Oncogenic PI3Kα variants reveal graded conformational spectrum with mutation-specific cryptic pockets

    by Hyunbum Jang, Bengi Ruken Yavuz, Mingzhen Zhang, Yonglan Liu, Ruth Nussinov

    Cancer-prone alleles exhibit single hotspot mutations. However, the combination of a cancer hotspot and a weak or moderate mutation (the ‘one-two punch’ hypothesis) produces same-allele double variants with a significantly different and potentially graded clinical phenotypic spectrum. Oncogenic PI3Kα variants, which are also associated with benign tumors and neurodevelopmental disorders, offer statistical support for this model. Using atomistic molecular dynamics (MD) simulations, we revealed that PI3Kα variants with single and double mutations exhibit expanded conformational profiles. Double mutations significantly shift the conformational ensembles toward the active form—a more pronounced effect than a single mutation. These double mutants facilitate nSH2 release, iSH2 shift, and A-loop protrusion in solution, promoting PIP 2 substrate recruitment at the membrane. Our simulations revealed cryptic pockets within PI3Kα. These pockets are potential drug targets and may exhibit mutation-specific characteristics. A key challenge is that a single drug is often ineffective against PI3Kα variants due to their diverse conformational spectra. To address this, we propose a conformational selection strategy involving a combination of allosteric drugs for variants with graded conformational spectra, particularly those with strong double mutations; we identified such potentially targetable cryptic pockets in double mutants conformers .


  • Open Access

    Cellular Mechanisms Underlying Melanoma Brain Metastasis

    by Bengi Ruken Yavuz, Hyunbum Jang, Ruth Nussinov

    Brain metastasis is a major contributor to melanoma-related mortality, arising from both genomic alterations and dynamic adaptations to the brain microenvironment. Tumor cells must cross the blood–brain barrier and exploit brain-specific signaling and metabolic landscapes to establish metastases. Brain metastases display molecular and phenotypic programs distinct from other organs, reflecting pre-existing and acquired mutations during progression. We analyzed primary melanoma, metastatic melanoma, and metastatic brain tumors genomic datasets to identify mutated proteins and signaling pathways that are common to or distinct among these tumor types. Our comprehensive computational analyses uncovered key pathways and proteins associated with brain metastasis. Brain metastases exhibit unique mutational landscapes and convergent alterations in neurotrophin, MAPK, and PI3K/AKT signaling compared with primary and metastatic melanoma. Proteins especially frequent in brain metastases pathways support survival, proliferation, and adaptation in the brain microenvironment. Pharmacology-wise, rational strategies such as combining c-KIT and VEGFR inhibitors can suppress converging oncogenic pathways and mitigate resistance in advanced melanoma. Co-targeting neurotrophin receptors with MAPK pathway members, particularly in combination with BRAF inhibitors, appears a promising approach for treating melanoma brain metastases. Our findings underscore the molecular heterogeneity of melanoma brain metastases, shaped by interconnected signaling networks , and reveal therapeutic targets that may diverge from those in other metastatic sites .


  • Open Access

    Discovering anticancer drug target combinations via network-informed signaling-based approach

    by Bengi Ruken Yavuz, Hyunbum Jang, Ruth Nussinov

    Background Oncologists deciding on cancer treatments must make difficult decisions as to which prescription and implementation strategies would best suit each patient. Much is still unknown about combinations of prescription drugs as there are many to choose from. At the outset, the oncologist reckons with at least two established facts: (i) patients receiving successive single molecules treatments are likely to experience drug resistance, and (ii), to select optimal drug combinations requires to pick the ‘best’ protein drug target combinations. Intuitively, target selection should precede drug selection, implying that well-informed strategies would opt to first consider drug targets — not drugs — combinations. Nowadays, drug combinations that oncologists consider are empirical and limited. They are restricted primarily by observations and praxis, that is, scant clinical experience with their application. Methods Here we develop a strategy for selecting optimal drug target combinations following nature. We use protein-protein interaction networks and shortest paths to discover communication pathways in cells based on interaction network topology. Our strategy mimics cancer signaling in drug resistance, which commonly harnesses pathways parallel to those blocked by drugs, thereby bypassing them. Results We select key communication nodes as combination drug targets inferred from topological features of networks. We test our network-informed signaling-based approach to discover anticancer drug target combinations on available clinical data, patient-derived breast and colorectal cancers. Alpelisib + LJM716 and alpelisib + cetuximab + encorafenib combinations diminish tumors in breast and colorectal cancers, respectively. Conclusions Our network-based approach discovers optimal protein co-target combinations to counter resistance, selecting co-targets from alternative pathways and their connectors.


  • Open Access

    Oncogenic PI3Kα variants reveal graded conformational spectrum with mutation-specific cryptic pockets

    by Hyunbum Jang, Bengi Ruken Yavuz, Mingzhen Zhang, Yonglan Liu, Ruth Nussinov

    Cancer-prone alleles exhibit single hotspot mutations. However, the combination of a cancer hotspot and a weak or moderate mutation (the ‘one-two punch’ hypothesis) produces same-allele double variants with a significantly different and potentially graded clinical phenotypic spectrum. Oncogenic PI3Kα variants, which are also associated with benign tumors and neurodevelopmental disorders, offer statistical support for this model. Using atomistic molecular dynamics (MD) simulations, we revealed that PI3Kα variants with single and double mutations exhibit expanded conformational profiles. Double mutations significantly shift the conformational ensembles toward the active form—a more pronounced effect than a single mutation. These double mutants facilitate nSH2 release, iSH2 shift, and A-loop protrusion in solution, promoting PIP 2 substrate recruitment at the membrane. We discovered that observable, potentially drug-targetable cryptic pockets are PI3Kα mutation-specific. Ab initio discovery of these pockets through simulations is essential for AI-aided virtual drug screening. A key challenge is that a single drug is often ineffective against PI3Kα variants due to their diverse conformational spectra. To address this, we propose a conformational selection strategy involving a combination of allosteric drugs for variants with graded conformational spectra, particularly those with strong double mutations; we identified such potentially targetable cryptic pockets in double mutants conformers .


  • Open Access

    Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery

    by Bengi Ruken Yavuz, Hyunbum Jang, Ruth Nussinov

    While anticancer drug discovery has seen dramatic innovations and successes, sequential single therapies are time-limited by resistance, and combinatorial strategies have been lagging. The number of possible drug combinations is vast. To select drug combinations the oncologist requires knowledge of the optimal combination of proteins to co-target. Currently, combinations that the oncologist considers are primarily from empirical observations and clinical praxis. Our aim is to develop a signaling-based method to discover optimal proteins for the oncologist to co-target with drug combinations, and test it on available, patient-derived data. To temper the expected resistance to single drug regimen, we offer a concept-based stratified pipeline aimed at selecting co-targets for drug combinations. Our strategy is unique in its co-target selection being based on signaling pathways. This is significant since in cancer, drug resistance commonly bypasses blocked proteins by wielding alternative, or complementary, routes to execute cell proliferation. Our network-informed signaling-based approach harnesses advanced network concepts and metrics, and our compiled, tissue-specific co-existing mutations. Co-existing driver mutations are common in resistance. Thus, to mimic cancer and counter drug resistance scenarios, our pipeline seeks co-targets that when targeted by drug combinations, can shut off cancer’s modus operandi . That is, its parallel or complementary signaling pathways would be blocked. Rotating through combinations could further lessen emerging resistance. We applied it to patient-derived breast and colorectal ESR1 | PIK3CA and BRAF | PIK3CA subnetworks. Consistently, in breast cancer, our results suggest co-targeting proteins from the ESR1|PIK3CA subnetwork with an alpelisib-LJM716 combination. In colorectal cancer, they co-target BRAF | PIK3CA with alpelisib, cetuximab, and encorafenib combination. Collectively, our pipeline’s results are promising, and validated by patient-based xenografts. GRAPHICAL


  • Open Access

    Neurodevelopmental disorders and cancer networks share pathways, but differ in mechanisms, signaling strength, and outcome

    by Bengi Ruken Yavuz, M. Kaan Arici, Habibe Cansu Demirel, Chung-Jung Tsai, Hyunbum Jang, Ruth Nussinov, Nurcan Tuncbag

    Epidemiological studies suggest that individuals with neurodevelopmental disorders (NDDs) are more prone to develop certain types of cancer. Notably, however, the case statistics can be impacted by late discovery of cancer in individuals afflicted with NDDs, such as intellectual disorders, autism, and schizophrenia, which may bias the numbers. As to NDD-associated mutations, in most cases, they are germline while cancer mutations are sporadic, emerging during life. However, somatic mosaicism can spur NDDs, and cancer-related mutations can be germline. NDDs and cancer share proteins, pathways, and mutations. Here we ask (i) exactly which features they share, and (ii) how, despite their commonalities, they differ in clinical outcomes. To tackle these questions, we employed a statistical framework followed by network analysis. Our thorough exploration of the mutations, reconstructed disease-specific networks, pathways, and transcriptome levels and profiles of autism spectrum disorder (ASD) and cancers, point to signaling strength as the key factor: strong signaling promotes cell proliferation in cancer, and weaker (moderate) signaling impacts differentiation in ASD. Thus, we suggest that signaling strength, not activating mutations, can decide clinical outcome.


  • Open Access

    Neurodevelopmental disorders and cancer networks share pathways; but differ in mechanisms, signaling strength, and outcome

    by Bengi Ruken Yavuz, M Kaan Arici, Habibe Cansu Demirel, Chung-Jung Tsai, Hyunbum Jang, Ruth Nussinov, Nurcan Tuncbag

    Neurodevelopmental disorders (NDDs) and cancer are connected, with immunity as their common factor. Their clinical presentations differ; however, individuals with NDDs are more likely to acquire cancer. Schizophrenia patients have ∼50% increased risk; autistic individuals also face an increased cancer likelihood. NDDs are associated with specific brain cell types at specific locations, emerging at certain developmental time windows during brain evolution. Their related mutations are germline; cancer mutations are sporadic, emerging during life. At the same time, NDDs and cancer share proteins, pathways, and mutations. Here we ask exactly which features they share, and how despite their commonality, they differ in outcomes. Our pioneering bioinformatics exploration of the mutations, reconstructed disease-specific networks, pathways, and transcriptome profiles of autism spectrum disorder (ASD) and cancers, points to elevated signal strength in pathways related to proliferation in cancer, and differentiation in ASD. Signaling strength, not the activating mutation, is the key factor in deciding cancer versus NDDs.

  • Open Access

    Discovery of Latent Drivers from Double Mutations in Pan-Cancer Data Reveal their Clinical Impact

    by Bengi Ruken Yavuz, Chung-Jung Tsai, Ruth Nussinov, Nurcan Tuncbag

    Background Transforming patient-specific molecular data into clinical decisions is fundamental to personalized medicine. Despite massive advancements in cancer genomics, to date driver mutations whose frequencies are low, and their observable transformation potential is minor have escaped identification. Yet, when paired with other mutations in cis , such ‘latent driver’ mutations can drive cancer. Here, we discover potential ‘latent driver’ double mutations. Method We applied a statistical approach to identify significantly co-occurring mutations in the pan-cancer data of mutation profiles of ∼80,000 tumor sequences from the TCGA and AACR GENIE databases. The components of same gene doublets were assessed as potential latent drivers. We merged the analysis of the significant double mutations with drug response data of cell lines and patient derived xenografts (PDXs). This allowed us to link the potential impact of double mutations to clinical information and discover signatures for some cancer types. Results Our comprehensive statistical analysis identified 228 same gene double mutations of which 113 mutations are cataloged as latent drivers. Oncogenic activation of a protein can be through either single or multiple independent mechanisms of action. Combinations of a driver mutation with either a driver, a weak driver, or a strong latent driver have the potential of a single gene leading to a fully activated state and high drug response rate. Tumor suppressors require higher mutational load to coincide with double mutations compared to oncogenes which implies their relative robustness to losing their functions. Evaluation of the response of cell lines and patient-derived xenograft data to drug treatment indicate that in certain genes double mutations can increase oncogenic activity, hence a better drug response (e.g. in PIK3CA), or they can promote resistance to the drugs (e.g. in EGFR). Conclusion Our comprehensive analysis of same allele double mutations in cancer genome landscapes emphasizes that interrogation of big genomic data and integration with the results of large-scale small-molecule sensitivity data can provide deep patterns that are rare; but can still result in dramatic phenotypic alterations, and provide clinical signatures for some cancer types.